Markets

Insider Trading

Hedge Funds

Retirement

Opinion

10 Best Low Price Pharma Stocks To Buy Now

In this article, we discuss 10 best low price pharma stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Low Price Pharma Stocks To Buy Now

The global pharmaceuticals market was forecasted to grow from $1454.66 billion in 2021 to $1587.05 billion in 2022 at a compound annual growth rate (CAGR) of 9.1%. As companies realign their operations and rebound from pandemic-driven constraints, the global pharmaceutical market is expected to reach $2135.18 billion in 2026 at a CAGR of 7.7%. While North America was the biggest region in the pharmaceuticals market in 2021, the Middle East is expected to be the quickest growing market in the forecast period.

According to the World Health Organization, one in every six people on the planet will be 60 or older by 2030. The population aged 60 and above will increase from 1 billion in 2020 to 2.2 billion by 2050. This significant elevation in the aging population will boost the number of patients with chronic diseases such as rheumatoid arthritis, hypertension, diabetes, and cancer. This will lead to an increase in the demand for pharmaceuticals used for the treatment of these diseases, which will meaningfully impact market growth in the future. 

According to McKinsey, drug spending has increased, and dispensing revenue grew from $450 billion in 2019 to $500 billion in 2021. The growth was mainly driven by specialty drugs, which are now responsible for 40% of the total dispensing revenue. Ongoing innovation in drug development could boost specialty profit even more, and these profit pools are anticipated to increase at an 8% CAGR from 2021 to 2025. New technology-led pharmacies have entered the market and are steadily gaining share, featuring direct-to-consumer models with digital prescription management, automated workflows, and swift home delivery services. These innovative pharmaceutical firms will prompt higher competition in the market, which can potentially enhance the business models of larger retail and mail pharmacies as well, offering margin upside. 

To benefit from the boom in the pharmaceutical industry, investors usually lean towards firms like Eli Lilly and Company (NYSE:LLY), Pfizer Inc. (NYSE:PFE), and Moderna, Inc. (NASDAQ:MRNA). However, in this article, we discuss some of the top low price pharma stocks, which offer the same bang for the buck. 

Pixabay/Public Domain

Our Methodology 

We selected the following low price pharma stocks based on positive analyst ratings, ongoing and pipeline projects, and future growth potential. These stocks were priced under $20 as of October 17. We have arranged the list according to the hedge fund sentiment around the securities, which was assessed from Insider Monkey’s Q2 2022 database of about 900 elite hedge funds. 

Best Low Price Pharma Stocks To Buy Now

10. Evotec SE (NASDAQ:EVO)

Number of Hedge Fund Holders: 1

Share Price as of October 17: $8.31

Evotec SE (NASDAQ:EVO) is a German drug discovery and development company partnering with pharmaceutical and biotechnology firms worldwide. The company is creating pharmaceutical products in multiple therapeutic areas, such as diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, respiratory diseases, and women’s health. Evotec SE (NASDAQ:EVO) is one of the best low price pharma stocks to invest in. 

On October 17, Toronto Innovation Acceleration Partners (TIAP) and Evotec SE (NASDAQ:EVO) announced that they had expanded their translational BRIDGE partnership LAB150, to sign on Amgen Inc. (NASDAQ:AMGN) as a strategic partner. The expansion will result in an investment of $14 million to expedite LAB150 programs for creating new life science companies. On September 21, Evotec SE (NASDAQ:EVO) announced that it is collaborating with Adapsyn Bioscience to get access to novel drug-like small molecules from microorganisms. The multi-year collaboration will provide Evotec SE (NASDAQ:EVO) several bioactive small molecules to screen against high value targets. 

Citi analyst Peter Verdult on September 13 maintained a Neutral rating on Evotec SE (NASDAQ:EVO) and trimmed the price target on the shares to EUR 28 from EUR 30. 

According to Insider Monkey’s data, Cathie Wood’s ARK Investment Management held 11,458 shares of Evotec SE (NASDAQ:EVO) at the end of the second quarter of 2022, worth $316,000. 

Like Eli Lilly and Company (NYSE:LLY), Pfizer Inc. (NYSE:PFE), and Moderna, Inc. (NASDAQ:MRNA), Evotec SE (NASDAQ:EVO) is one of the best pharma stocks to watch.

9. Theratechnologies Inc. (NASDAQ:THTX)

Number of Hedge Fund Holders: 4

Share Price as of October 17: $2.06

Theratechnologies Inc. (NASDAQ:THTX) was incorporated in 1993 and is headquartered in Montreal, Canada. It is a biopharmaceutical company that focuses on the development and commercialization of multiple therapies to address unmet medical needs in the United States, Canada, and Europe. Theratechnologies Inc. (NASDAQ:THTX) primarily specializes in the treatments for HIV-1, breast cancer, and ovarian cancer. Theratechnologies Inc. (NASDAQ:THTX) is one of the top low price pharma stocks to buy. 

On October 13, Theratechnologies Inc. (NASDAQ:THTX) reported a Q3 revenue of $20.81 million, up 16.6% year-over-year, beating market estimates by $0.07 million. There was a 19% revenue growth in the North American market. Given the elevation in revenue and the relatively smaller increase in expenses in Q3 2022, net loss came in at $7.55 million, down from $9.51 million in the prior year quarter. Theratechnologies Inc. (NASDAQ:THTX) also reiterated its revenue guidance for the full-year 2022, expecting it to be in the range of $79 million to $82 million, versus a consensus of $79.49 million. The growth of the commercial portfolio is forecasted to be 13%-17% higher as compared to the 2021 fiscal year.

Theratechnologies Inc. (NASDAQ:THTX) announced on October 3 that the United States Food and Drug Administration authorized Trogarzo for administration by intravenous push, a method by which the undiluted medication is “pushed” by syringe for faster administration into the body’s circulation.

According to Insider Monkey’s data, Theratechnologies Inc. (NASDAQ:THTX) was part of 4 hedge fund portfolios at the end of Q2 2022, compared to 6 funds in the prior quarter. Guy Levy’s Soleus Capital is the leading position holder in the company, with 7.82 million shares worth $17.75 million. 

8. Alimera Sciences, Inc. (NASDAQ:ALIM)

Number of Hedge Fund Holders: 5

Share Price as of October 17: $5.43

Alimera Sciences, Inc. (NASDAQ:ALIM) is a Georgia-based pharmaceutical company engaged in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. On October 6, Alimera Sciences, Inc. (NASDAQ:ALIM) announced that a post-hoc analysis from a Phase 4 study indicated that median treatment frequency in diabetic macular edema patients treated with its therapy Iluvien 0.19 mg was lower than from patients on other regimens. Alimera Sciences, Inc. (NASDAQ:ALIM), trading at under $6 per share as of October 17, is one of the best low price pharma stocks to buy now. 

H.C. Wainwright analyst Yi Chen on July 28 raised the price target on Alimera Sciences, Inc. (NASDAQ:ALIM) to $9 from $8 and reiterated a Buy rating on the shares. The analyst cited the company’s “solid” sales growth in Q2 2022 for the target raise.

According to Insider Monkey’s data, 5 hedge funds held stakes worth $2.90 million in Alimera Sciences, Inc. (NASDAQ:ALIM) at the end of the second quarter of 2022, compared to 3 funds in the prior quarter worth $1.82 million. William Leland Edwards’ Palo Alto Investors is the biggest position holder in the company, with 200,919 shares valued at $1.09 million. 

7. Alpha Teknova, Inc. (NASDAQ:TKNO)

Number of Hedge Fund Holders: 6

Share Price as of October 17: $3.23

Alpha Teknova, Inc. (NASDAQ:TKNO) was founded in 1996 and is headquartered in Hollister, California. The company provides critical reagents for the life sciences market in the United States and internationally, enabling the discovery, development, and production of biopharmaceutical products, including drug therapies, novel vaccines, and molecular diagnostics. 

On October 13, Alpha Teknova disclosed creating an Early Access Program for two new products currently in development to streamline downstream gene therapy process development, including an Anion Exchange Buffer Screening Kit and a Functional Reporter Assay. Alpha Teknova, Inc. (NASDAQ:TKNO) is one of the top low price pharma stocks to monitor. 

Stephens analyst Jacob Johnson on August 11 reaffirmed an Overweight rating on Alpha Teknova, Inc. (NASDAQ:TKNO) but slashed the price target on the shares to $15 from $22. While Alpha Teknova, Inc. (NASDAQ:TKNO)’s Q2 revenue and adjusted EBITDA outperformed expectations, the company retracted FY22 revenue expectations on the back of delayed orders from a group of CGT customers, implying that second half revenues will be considerably below the first half, the analyst told investors in a research note. The analyst remains bullish on the long-term outlook for cell and gene therapy and said that Alpha Teknova, Inc. (NASDAQ:TKNO) is a solid derivative consumables play in the end-market.

Among the hedge funds tracked by Insider Monkey, 6 funds were long Alpha Teknova, Inc. (NASDAQ:TKNO) at the end of Q2 2022, compared to 7 funds in the last quarter. Israel Englander’s Millennium Management is the leading stakeholder of the company, with 656,981 shares worth $5.5 million. 

6. Grifols, S.A. (NASDAQ:GRFS)

Number of Hedge Fund Holders: 12

Share Price as of October 17: $6.14

Grifols, S.A. (NASDAQ:GRFS) was founded in 1940 and is headquartered in Barcelona, Spain. The company engages in the procurement, manufacture, and sale of therapeutic products, operating through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. On September 7, Grifols, S.A. (NASDAQ:GRFS) announced a long-term agreement with Canada’s national blood authority to increase the availability of immunoglobulin medicines and plasma-protein therapies in the country. The plasma sourcing capacity in Canada will expand to provide 2.4 million grams of immunoglobulin medicine annually by 2026. 

On October 7, Morgan Stanley analyst Sarita Kapila maintained an Equal Weight rating on Grifols, S.A. (NASDAQ:GRFS) and trimmed the price target on the shares to EUR 13 from EUR 20. 

According to Insider Monkey’s data, 12 hedge funds were bullish on Grifols, S.A. (NASDAQ:GRFS) at the end of Q2 2022, compared to 10 funds in the preceding quarter. Israel Englander’s Millennium Management is the leading position holder in the company, with 7.4 million shares worth $88.4 million. 

In addition to Eli Lilly and Company (NYSE:LLY), Pfizer Inc. (NYSE:PFE), and Moderna, Inc. (NASDAQ:MRNA), smart investors are monitoring Grifols, S.A. (NASDAQ:GRFS) in the pharma sector. 

Click to continue reading and see 5 Best Low Price Pharma Stocks To Buy Now

Suggested articles:

Disclosure: None. 10 Best Low Price Pharma Stocks To Buy Now is originally published on Insider Monkey.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

  • It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
  • It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
  • It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

  • The AI infrastructure supercycle
  • The onshoring boom driven by Trump-era tariffs
  • A surge in U.S. LNG exports
  • And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!